CytoDyn Inc. (CYDY): Cash & Equivalents
$11.85M
As of 2026-05-31
+67.1%
3-year compound annual growth
-19.0%
5-year compound annual growth
+2.1%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-05-31 | $11.85M | -0.4% | 2026-08-31, Balance as of period end |
| 2025-05-31 | $11.90M | +282.7% | 2026-08-31, Balance as of period end |
| 2024-05-31 | $3.11M | +22.4% | 2025-07-25, Balance as of period end |
| 2023-05-31 | $2.54M | -39.9% | 2024-08-15, Balance as of period end |
| 2022-05-31 | $4.23M | -87.5% | 2023-09-14, Balance as of period end |
| 2021-05-31 | $33.94M | +137.7% | 2022-08-15, Balance as of period end |
| 2020-05-31 | $14.28M | +446.6% | 2022-08-15, Balance as of period end |
| 2019-05-31 | $2.61M | +112.2% | 2021-07-30, Balance as of period end |
| 2018-05-31 | $1.23M | -30.6% | 2019-08-14, Balance as of period end |
| 2017-05-31 | $1.78M | -81.6% | 2018-07-27, Balance as of period end |
| 2016-05-31 | $9.64M | +818.2% | 2018-07-27, Balance as of period end |
| 2015-05-31 | $1.05M | -78.5% | 2016-07-19, Balance as of period end |
| 2014-05-31 | $4.89M | +709.4% | 2015-07-10, Balance as of period end |
| 2013-05-31 | $603.7K | +111.8% | 2014-07-10, Balance as of period end |
| 2012-05-31 | $285.0K | -72.5% | 2013-08-29, Balance as of period end |
| 2011-05-31 | $1.04M | +48.2% | 2013-08-29, Balance as of period end |
| 2010-05-31 | $700.5K | n/a | 2012-08-22, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| CytoDyn Inc. (CYDY) | 2026-05-31 | $11.85M | -0.4% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $13.16M | +52.3% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $7.56M | +24.6% |
| Biovie Inc. (BIVI) | 2026-06-30 | $8.98M | -48.8% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $11.52M | +45.2% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $10.80M | +980.0% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $13.20M | -43.3% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
| Cingulate Inc. (CING) | 2025-12-31 | $10.95M | -10.3% |
Compare CYDY, ACTU, CMMB, BIVI side by side · Screen every company in Pharmaceutical Preparations ↗